Join us at IMSC2022. Meet our users, in-house experts and collaboration partners at our 4D-Proteomics™ seminar.
As they rely on the use of Parallel Accumulation Serial Fragmentation (PASEF®) -based methods, 4D-Proteomics™ approaches are capable of acquiring peptide MS/MS spectra simultaneously with an extremely high acquisition speed, an increased selectivity and a best-in class sensitivity.
Moreover, an accurate Collisional Cross Section (CCS) is measured for each peptide: its use in the bioinformatic processing pipeline allows to further increase identification sensitivity and quantification accuracy. Learn how those approaches can be used to obtain more information from some of the most challenging proteomics task: from single-cell research to plasma-based diagnosis and crosslinked peptides analysis.
Our speakers will be Prof. Nikolai Slavov from the Northeastern University (Boston, MA, USA) "Increasing the throughput of sensitive proteomics by plexDIA”, Dr. Hans Wessels from the Radboud University Medical Centre (Nijmegen, Netherlands) "Real-time PASEF DDA and DIA data processing by Bruker ProteoScape™ for clinical applications" and Dr. Richard Scheltema from the Netherland Proteomics Centre (Utrecht, Netherlands) “Leveraging the timsTOF Pro to study lung disease”.
Increasing the throughput of sensitive proteomics by plexDIA
Prof. Dr. Nikolai Slavov, Allen Distinguished Investigator and Associate Professor, Northeastern University, Boston, MA, USA
Current mass-spectrometry methods enable high-throughput proteomics of large sample amounts, but proteomics of low sample amounts remains limited in depth and throughput. To increase the throughput of sensitive proteomics, we developed an experimental and computational framework, plexDIA, for simultaneously multiplexing the analysis of both peptides and samples. Multiplexed analysis with plexDIA increases throughput multiplicatively with the number of labels without reducing proteome coverage or quantitative accuracy. By using 3-plex nonisobaric mass tags, plexDIA enables quantifying 3-fold more protein ratios among nanogram-level samples. When applied to single human cells using timsTOF SCP, plexDIA quantified about 1,000 proteins per cell and achieved 98 % data completeness within a plexDIA set while using about 5 min of active chromatography per cell. These results establish a general framework for increasing the throughput of sensitive and quantitative protein analysis.
Real-time PASEF DDA and DIA data processing by Bruker ProteoScape™ for clinical applications
Dr. Hans Wessels, Proteomics scientist, Radboud University Medical Centre, Nijmegen, Netherlands
Molecular diagnostics is a key asset in personalized healthcare to diagnose disease and to ensure that each individual receives the right treatment at the right time. Recent developments in mass spectrometry hardware enabled robust high-throughput acquisition of comprehensive clinically-compliant proteomics data. This paradigm shift from single molecule to proteome-scale data acquisition leads functional diagnostics into a new era of laboratory medicine. The main bottleneck for implementation in clinical practice is however a lack of efficient data workflows to translate complex omics data into lucid personalized test-reports. Here we will share our first results for personalized M-protein diagnostics in Multiple Myeloma (MM) patients using the GPU powered parallel computing solution “Bruker ProteoScape™” to solve downstream data challenges.
Leveraging the timsTOF Pro to study lung disease
Dr. Richard Scheltema, Associate Professor in Structural Proteomics, Netherlands Proteomics Centre, Utrecht, Netherlands
As a first line of defense, small airways homeostasis is critical to lung functionality. Pathological changes of the cellular and ECM components in the small airways are often seen in chronic respiratory diseases such as COPD. Mechanistic understanding of these changes is key to developing novel therapies; however, the landscape of healthy and diseased lungs at the proteomics level remains elusive. By using a combination of laser-capture microdissection and state-of-the-art mass spectrometry with the timsTOF Pro we were able to measure low complexity, low sample input samples to great depth and uncover modulation of the ECM and cellular receptors linked to different stages of COPD.
Whether you are probing the cellular proteome, lipidome or metabolome, MALDI Imaging provides a literal map of molecular expression in the specimen that can be compared to reveal regional changes.
Often, knowing where molecular expression changes can be just as important as knowing if expression changes. This can be especially true if certain compounds are highly spatially concentrated or if molecules co-distribute in specific compartments, vital information that is lost when examining only homogenized samples.
Bruker offers solutions for targeted and untargeted discovery with the most complete molecular range and contextualized spatial information, providing important clues into intercellular communications networks that are integral to cancer growth.
To target or not to target: translational imaging & “omics” of single cells
Prof. Dr. Ron Heeren, Director and Division Head Imaging Mass Spectrometry, Maastricht MultiModal Molecular Imaging Institute, M4i, Maastricht University, Maastricht, Netherlands
What is more important: the target or the context? Recent developments in the combination of untargeted (unlabelled) and targeted (using labelled antibodies) mass spectrometry based imaging is revolutionizing complementary imaging and “Omics”. New capabilities that improve throughput and content assist in accelerating the pickup of these new approaches in digital pathology. MS image guided tissue selection, with laser capture microdissection, followed by in-depth metabolomics (or proteomics) analysis is added to this workflow to provide detailed insight in local molecular signalling pathways. In this lecture recent advances and applications in the field of translational molecular imaging in a clinical and immunological setting will be discussed.
MALDI Imaging Mass Spectrometry in Pharmaceutical Research & Development
Prof. Dr. Carsten Hopf, Center for Mass Spectrometry and Optical Spectroscopy (CeMOS), Mannheim University of Applied Sciences, Mannheim and Medical Faculties, Heidelberg University, Germany
MALDI MS Imaging (MSI) has recently emerged as a key label-free and fast technology for the assessment of spatial distribution of (onco-) metabolites, N-glycans, lipids, drugs, drug metabolites in preclinical animal models of disease and in human tissue specimen. MSI provides molecular specificity information by ultra-high resolution MS, e.g. magnetic resonance MS, or trapped ion mobility MS. Part 1 of the talk will present recent pharmacology applications of (quantitative) MSI in spatial drug and onco-metabolite analysis and highlight the use of MSI in spatial analysis of tissue enzyme function.
Current developments of MSI technology for pharma research & development will be explored in part 2 of the talk: 3D-reconstructions combined with computational analysis, bioanalysis of 3D-cell culture models of disease, the coupling of MSI with laser microdissection and LC-MS (spatialomics), and multiplex-MALDI MS-immunohistochemistry.
August 31, 2.45 - 3.00 CEST: Spatial Metabolite-ID in pharmaceutical applications
Dr. Tiffany Siegel, Scientist - Mass Spectrometry Imaging at Boehringer Ingelheim Pharma GmbH, Biberach an der Riss, Germany
Metabolite identification is an important step within drug discovery and development. Traditionally, LC-MS-based analytics of body fluids (e.g. plasma, bile, urine) are the dominant technology in this field. We show how metabolite detection in tissue can enhance this approach by combining LC-MS-based identification of metabolites from tissue homogenates with metabolite localization by MALDI-MSI on a single platform in a Spatial Omics-like scenario.
September 1, 2.45 - 3.00 CEST: Applying Immunopeptidomics to predict clinical immunogenicity
Dr. Duong Nguyen, Octapharma Biopharmaceuticals GmbH, Berlin, Germany
Therapeutic proteins have the potential to induce an anti-drug antibody response that can neutralize the therapeutic effects and contribute to hypersensitivity in patients.
To assess the immunogenicity potential of our therapeutic candidates we apply immunopeptidomics for the identification of immunogenic hotspots and for unravelling the mechanisms that cause immunogenicity.
Due to unprecedented demand for our M4i MALDI Imaging lab tour, we unfortunately had to close online registrations earlier than expected but are still able to offer an opportunity to those that did not receive confirmations.
Would you like to visit the M4i facility, the Maastricht MultiModal Molecular Imaging Institute, and see how the rapifleX® and timsTOF fleX are used to improve translational research and pharma applications? Come and see us at Bruker booth #4 (Main Exhibition Hall) from Sunday, August 28th to register or confirm your registration!
The M4i is a state-of-the art international institute that brings together a powerful palette of innovative molecular imaging technologies for translational medicine and development of diagnostic and prognostic tools for personalized medicine in oncology, neurology and cardiovascular medicine, as well as innovative pharma applications. See how the rapifleX® and timsTOF fleX play a key role in achieving the institute's goals by expanding the applications of Imaging Mass Spectrometry.
The tours will start at the Bruker booth #4 (Main Exhibition Hall):
The number of participants is limited to 10 per tour, so be the first to come by Bruker booth #4 (Main Exhibition Hall) from Sunday, August 28th to register (and say hello)!
Bruker Daltonics is pleased to announce the first ever Jochen Franzen Award, dedicated to the life and work of Bruker’s mass spectrometry founder, inventor, and innovator Dr. Jochen Franzen (1931-2021). This accolade will be awarded for outstanding contributions to innovations in structural, spatial and/or separation analysis with mass spectrometry to honor the great scientific achievements of Dr. Franzen.
Jochen Franzen, son of Werner and Ruth Franzen, was born on the 28th of January 1931 in Witten in the Ruhr District of Germany. Dr. Franzen grew up in Thüringen, Germany, and graduated from his doctoral studies in Physics from Mainz in 1963. In 1977, Dr. Franzen founded the Franzen Analysentechnik GmbH in Bremen and consequently three years later joined forces with Bruker. With this, Bruker-Franzen Analytik GmbH was created in Bremen, Germany, specializing in the invention and manufacturing of mass spectrometry instrumentation.
Dr. Franzen was known for his commitment to continuous innovation, demonstrated in his more than 190 patents granted across his impressive and long career. One such achievement was the invention, development and manufacture of a glass quadrupole used for GC-MS that could be mounted on a tank for the detection of chemical warfare agents. This went on to sell more than 500 units and positively impacted the field of mobile mass spectrometry. Under Dr. Franzen’s leadership, Bruker received large development and production contracts from the US army for CBMS, a chemical-biological mass spectrometer that represented a technological leap over existing chemical agent detection platforms. The CBMS platform was built on ion trap technology with non-linear ion ejection that used MS/MS to reject false positive indications that would reduce troop effectiveness. Dr. Franzen used a new measuring principle called the “ion cage” that simultaneously enabled instrument miniaturization and the greatest possible degree of automation of use. In doing so, he opened new application areas including the analysis of multi-component mixtures and biological materials.
Bruker’s TOF development was initiated by Dr. Franzen using MALDI for which Bruker is widely recognized as the market leading provider of MALDI-TOF solutions for a wide variety of applications. Today, Bruker has multiple mass spectrometry technologies including quadrupole, TOF, MRMS and timsTOF platforms that incorporate many of Dr. Franzen’s ideas. Thanks to the scientific and entrepreneurial achievements of Dr. Franzen, Bremen is today a leading center for the development and production of mass spectrometers. Since 2021, the site has been known as Bruker Daltonics GmbH & Co. KG and is one of the main R&D and production facilities for mass spectrometry worldwide with more than 500 employees.
A pioneer of mass spectrometry, Dr. Franzen’s more than 50 publications are foundational to the basic research in this field and are cited with above-average frequency. The first spectrometers he developed can be admired in the Deutsches Museum in Munich.
Dr. Jochen Franzen sadly passed away on September 24, 2021. The Bruker family will miss him dearly.
The Jochen Franzen award prize of 5000€ will be presented during IMSC, Maastricht, Netherlands on August 31 at 08.30 – 10.00 am CEST.
Come and visit Booth No. 2 in the Expo Foyer and Booth No. 4 in the main exhibition hall and talk to our specialists.
For Research Use Only. Not for use in clinical diagnostic procedures.